Get the Stockscreener App
3.00
2.60%
-0.08
After Hours:
3.12
0.12
+4.00%
Cns Pharmaceuticals Inc stock is traded at $3.00, with a volume of 11,294.
It is down -2.60% in the last 24 hours and down -34.07% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$3.08
Open:
$3.0177
24h Volume:
11,294
Relative Volume:
0.32
Market Cap:
$1.86M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.0424
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
-2.28%
1M Performance:
-34.07%
6M Performance:
-51.53%
1Y Performance:
-89.92%
1-Day Range:
$2.87
$3.0316
1-Week Range:
$2.87
$3.2401
52-Week Range:
$2.87
$55.20
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
3.00 | 1.91M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
CNS Pharmaceuticals (CNSP) files insider Form 3 for Chief Financial Officer - Stock Titan
CNSP Financials: Income Statement, Balance Sheet & Cash Flow | CNS Pharmaceuticals - Stock Titan
CNS Pharmaceuticals Appoints New Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) appoints new CMO Lynne Kelley - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints New Executive Leadership Team - Digital Journal
CNS Pharmaceuticals appoints Lynne Kelley as CMO - TipRanks
CNS Pharmaceuticals names Lynne Kelley as chief medical officer - Investing.com
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team - ACCESS Newswire
Brain cancer drug developer hires veteran surgeon to lead studies - Stock Titan
CNSPCNS Pharmaceuticals Latest Stock News & Market Updates - Stock Titan
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm
Price Action: Will CNS Pharmaceuticals Inc stock go up in YEARGDP Growth & Smart Investment Allocation Tips - baoquankhu1.vn
Breakout Watch: Is CNS Pharmaceuticals Inc currently under institutional pressure2025 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn
Is CNS Pharmaceuticals Inc. forming a bullish divergence2025 AllTime Highs & Expert Verified Movement Alerts - mfd.ru
Drug-Delivery Breakthroughs, Cross-Indication Research - GlobeNewswire
Chart Watch: How does CNS Pharmaceuticals Inc perform in inflationary periodsGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
CNS Pharmaceuticals appoints three new executives to leadership team - Investing.com South Africa
CNS Pharmaceuticals appoints three new executives to leadership team By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals Inc. (ACAD) Investor Outlook: Potential 41.67% Upside Amid Robust CNS Drug Portfolio - DirectorsTalk Interviews
CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO - TipRanks
CNS Pharmaceuticals Restructures Finance Leadership, Appoints New CFO - TipRanks
CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 - marketscreener.com
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation - Yahoo Finance
Levels Update: Is CNS Pharmaceuticals Inc currently under institutional pressure2025 Performance Recap & Low Risk Growth Stock Ideas - baoquankhu1.vn
Is CNS Pharmaceuticals Inc. currently under institutional pressureFed Meeting & Free Long-Term Investment Growth Plans - mfd.ru
Is CNS Pharmaceuticals Inc. stock a smart buy before Fed meeting2025 Sector Review & Risk Managed Investment Strategies - mfd.ru
How CNS Pharmaceuticals Inc. stock performs in weak economy2025 Key Lessons & Stepwise Trade Signal Guides - mfd.ru
What are analysts’ price targets for CNS Pharmaceuticals Inc.July 2025 Opening Moves & Long Hold Capital Preservation Tips - mfd.ru
Why CNS Pharmaceuticals Inc. stock is recommended by analystsInsider Selling & Entry Point Strategy Guides - mfd.ru
CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 11.2% – Here’s What Happened - Defense World
Supernus Pharmaceuticals, Inc. (SUPN): Investor Outlook on CNS Drug Innovator with 19.56% Upside Potential - DirectorsTalk Interviews
CNS Pharmaceuticals Reports Financial Gains Amid Ongoing R&D - MSN
Growth Report: Will Origin Bancorp Inc outperform the market in YEARPrice Action & Community Verified Trade Signals - baoquankhu1.vn
Weekly Trades: Why is CNS Pharmaceuticals Inc stock going downJuly 2025 Price Swings & AI Powered Market Entry Strategies - baoquankhu1.vn
Aug Catalysts: Will CNS Pharmaceuticals Inc outperform small cap indexesQuarterly Earnings Summary & Weekly Hot Stock Watchlists - baoquankhu1.vn
Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals - GlobeNewswire
CNS Pharmaceuticals shares dip after CEO departure announcement - MSN
CNS Pharmaceuticals says priority ‘is to transform’ how company operates - TipRanks
CNS Pharmaceuticals’ new CEO outlines strategic overhaul By Investing.com - Investing.com Canada
CNS Pharmaceuticals (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287 - Digital Journal
CNS Pharmaceuticals Announces Strategic Review Focused on Lead Drug Candidate TPI 287 - citybuzz -
CNS Pharmaceuticals (CNSP) CEO Outlines Strategic Vision for Fut - GuruFocus
CNS Pharmaceuticals’ new CEO outlines strategic overhaul - Investing.com
CNS Pharmaceuticals Issues Letter to Shareholders - ACCESS Newswire
New CNS Pharmaceuticals CEO launches broad review built around lead cancer drug - stocktitan.net
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots - Seeking Alpha
Breakout Move: Is CNS Pharmaceuticals Inc stock good for income investorsMarket Volume Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Up 3.3% – What’s Next? - Defense World
Is CNS Pharmaceuticals Inc. being accumulated by smart money2025 Major Catalysts & Precise Buy Zone Identification - bollywoodhelpline.com
CNS Pharma Stock Up Over 30% - Nasdaq
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):